Diabetic mouse models

Yoshiaki Katsuda1, Takeshi Ohta1*, Masami Shinohara2, Tong Bin3, Takahisa Yamada3

1Japan Tobacco Inc., Central Pharmaceutical Research Institute, Takatsuki, Japan; *Corresponding Author: takeshi.ota@jt.com
2Planning and Development Section, CLEA Japan Inc., Tokyo, Japan
3Laboratory of Animal Genetics, Graduate School of Science and Technology, Niigata University, Niigata, Japan

Received 11 September 2013; revised 16 October 2013; accepted 26 October 2013

Copyright © 2013 Yoshiaki Katsuda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

The number of patients with lifestyle-related diseases, such as cardiovascular disease, diabetes mellitus, hypertension, atherosclerosis, and cancer, is increasing all over the world, and that of diabetics is increasing especially rapidly. Diabetic animal models have played a key role in elucidating the etiology of diabetes and developing anti-diabetic drugs. In this review, we overviewed characteristics of diabetic mouse models and pharmacological evaluation using the diabetic models.

Keywords: Diabetes; Diabetic Complication; Mouse Model; Obesity

1. INTRODUCTION

Diabetes has become a global health problem, and the incidence of diabetes is rapidly increasing in all regions of the world. The prevalence of diabetes across the world is forecast to increase from 171 million in 2000 to 366 million in 2030 [1].

Diabetes is classified into two categories: type 1 and type 2. Type 1 diabetes is characterized by a loss of insulin secretion due to pancreatic β-cell degeneration, leading to autoimmune attack. Type 2 diabetes is a metabolic disorder that is caused by insufficient insulin secretion and/or insulin resistance in peripheral and liver tissues [2].

To help develop new diabetic therapies, it is important to reveal the complex mechanisms of diabetes mellitus. In particular, investigations using diabetic animal models are essential to clarify the pathogenesis and progression in human disease course [3]. We reviewed nonobese diabetic (NOD) mouse and nonobese C57BL/6 mutant (Akita) mouse as type 1 diabetic models, and ob/ob mutant (db/db) mouse, KKAy mouse, and Tsumura Suzuki obese diabetes (TSOD) mouse as type 2 diabetic models, with respect to characteristic features and pharmacological evaluations using the diabetic models.

2. TYPE 1 DIABETIC MOUSE MODELS

It is known that type 1 diabetes is caused by autoimmune destruction of β cells of pancreas in genetically susceptible individuals. Understanding of the genetics and mechanisms of the disease has been facilitated by the use of nonobese diabetic (NOD) mouse. Another mouse model, nonobese C57BL/6 mutant (Akita) mouse, develops early age-onset diabetes, characterized by an autosomal dominant mode of inheritance.

2.1. NOD Mouse

2.1.1. Background and Characteristics

NOD mouse was established as an inbred strain of mouse with spontaneous development of autoimmune type 1 diabetes by Makino et al. in Shionogi laboratory [4]. The origin of the NOD traces back to a mouse with cataract among Jcl:ICR mice in 1966. Later, an inbred strain of mouse with cataracts and small eyes, the CTG mouse, was established by Ohtori et al. [5]. After selective breeding for hyperglycemia and euglycemia over about 10 generations, two sublines were transferred to Makino’s group, and strict brother-sister mating was started. At the 20th generation in selective breeding, a mouse with polyuria, polydipsia, and weight loss was found in the line with normal fasting blood glucose levels (approximately 100 mg/dl). Inbreeding was continued with this mouse to establish an inbred strain with spontaneous development of diabetes, which culminated in a strain currently known as the NOD mouse.

In NOD mice, infiltration of mononuclear cells into pancreatic islets, insulitis, was observed at about 4 weeks of age [6]. The infiltrating mononuclear cells were mostly T cells (CD4+ and CD8+), and macrophages were also observed. β cell destruction became aggressive after 15 weeks of age and overt diabetes developed. After the
onset of diabetes, NOD mice showed decreased body weight and died within one to two months unless treated with insulin injection [4]. Sex differences in incidence of diabetes existed, and the cumulative incidence of diabetes in Shionogi laboratory was approximately 80% in females and less than 20% in males at 30 weeks of age [4]. Moreover, diet, room temperature, and pathogens have been suggested as factors influencing the incidence of diabetes [7-9], but the exact causes are still unknown.

2.1.2. Pharmacological Evaluation

It was reported that thiazolidinediones (TZDs) reduced diabetes incidence in NOD mice [10,11]. Rosiglitazone and troglitazone both significantly reduced the diabetic incidence in NOD mice as compared with litter-matched control mice. The effect is considered to have been induced by anti-inflammatory properties of TZDs. Combined treatment with lisofyline to inhibit autoimmunity and exendin-4 to enhance β cell proliferation showed therapeutic effects in NOD mice [12]. Since NOD mice develop autoimmune-mediated inflammation of pancreatic islets, anti-inflammatory drugs are reported to be useful for prevention or treatment of diabetes in the mice [13,14].

2.2. Akita Mouse

2.2.1. Background and Characteristics

A nonobese C57BL/6 mutant mouse found in Akita colony, which spontaneously develops early age-onset diabetes, is characterized by an autosomal dominant mode of inheritance. In Akita mice, a diabetic locus named MODY4, was mapped to chromosome 7 in the region distal to D7Mit189 [15]. Akita mice develop diabetic symptoms, such as hyperglycemia, polydipsia, and polyuria, soon after weaning. The diabetic symptoms progress continuously in the male mice decreases gradually after about 25 weeks of age, and the rate at 52 weeks of age is about 20%. Neither infiltration of lymphocyte nor any signs of inflammatory reactions were detectable in pancreatic islets, anti-inflammatory drugs are reported to be useful for prevention or treatment of diabetes in the mice [15].

2.2.2. Pharmacological Evaluation

Recently, drug therapies for diabetic complications in Akita mice have been reported. Koshizaka et al. reported that telmisartan, an angiotensin II type 1 receptor blocker, prevented diabetic nephropathy through the inhibition of Notch pathway [24]. Furthermore, Chen et al. reported that fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, showed therapeutic effects on diabetic retinopathy in Akita mice [25]. Fenofibrate attenuated overexpression of intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1, and vascular endothelial growth factor (VEGF), and inhibited activation of hypoxia-inducible factor (HIF)-1 and nuclear factor (NF)-κB in retina of Akita mice.

3. TYPE 2 DIABETIC MOUSE MODELS

It is known that 90% - 95% of diabetes is diagnosed as type 2 diabetes [2]. Type 2 diabetes is a heterogeneous disease with multiple etiologies. The incidence and progression of diabetes characterized by insulin resistance and/or impaired insulin secretion are caused by genetic and environmental factors. The etiology is considered to be multigenetic rather than monogenic. The development of diabetic animal models and pathophysiologial analyses of the models are very important to aid in clarification of the pathogenesis and the patterns of progression in the human disease course. Diabetic mouse models, such as ob/ob mouse, db/db mouse, and KKAΔ mouse, are most commonly used in such studies.

3.1. Ob/Ob Mouse

3.1.1. Background and Characteristics

NOD Lepob mutation on chromosome 6 was discovered at the Jackson laboratory in a multiple recessive stock in 1949 [26], and the Lepob mutation was subsequently transferred to B6 inbred strain background [27]. Lepob mutation on the B6 background (ob/ob) mice
shows obesity, hyperinsulinemia, and relatively mild hypoglycemia.

Blood glucose levels in ob/ob mice increased as compared with those in lean mice from 7 to 11 weeks of age (Figure 1), but the levels decreased with aging and normalized after at about 12 weeks of age. The remission from hyperglycemia was correlated with a sustained hypertrophy of pancreatic islets or hyperinsulinemia. The abnormal adipose tissue enlargement with hyperphagia was observed in ob/ob mice [28]. De novo lipogenesis was markedly enhanced in ob/ob mice as compared with lean mice, and the hepatic fatty acid synthesis was increased 6-fold per total liver and 2.2-fold per total small intestine [29]. The lipolytic defect in adipose tissue was observed, and one of the reasons was considered to be β3-adrenergic receptor dysfunction in white adipose tissue [30].

3.1.2. Pharmacological Evaluation

There are some reports on anti-diabetic effects using ob/ob mice. Two-week treatment with vanadyl complex showed decreases in blood glucose, insulin, and triglyceride levels and ameliorated the impaired glucose tolerance [31]. The mechanism of the effects is considered to include attenuation of tumor necrosis factor (TNF)-α-induced decrease in insulin receptor substrate (IRS)-1 phosphorylation. Other compounds, such as glycogen phosphorylase inhibitor, β3 adrenoceptor agonist, and exendin-4, showed anti-diabetic effects in ob/ob mice [32-34]. We developed a protein tyrosine phosphatase (PTP)-1B inhibitor that shows an enhancement of insulin signaling, using ob/ob mice [35]. In ob/ob mice, PTP-1B inhibitor enhanced the insulin receptor-phosphorylation and showed the glucose-lowering effect (Figure 2).

3.2. db/db Mouse

3.2.1. Background and Characteristics

Leprdb mutation is a recessive mutation on chromosome 4 that occurred in C57BL KS/J inbred strain in 1966 [36]. The Leprdb mutation was subsequently transferred to the C57BL KS/J inbred strain by backcrossing. db/db mice resemble ob/ob mice in terms of a rapid development of obesity after weaning, but the diabetes syndrome is more severe. Blood glucose level at 7 weeks of age in db/db mice is about 700 mg/dl (Figure 3), and the hyperglycemia is sustained over the life span. The blood insulin levels increase from 7 to 9 weeks of age (Figure 3), but the insulin levels decrease gradually with aging. The transient hyperglycemia and the progressive hyperglycemia are correlated with morphological levels with pancreatic β cell necrosis and islet atrophy. Since the severe hyperglycemia is sustained in db/db mice, diabetic complications such as nephropathy and neuropathy are observed. The db/db mice had a decline in creatinine clearance after 20 weeks of age, and displayed substantial glomerular pathology, including mesangial expression and albuminuria [37,38]. There are some reports of neuropathy and retinopathy in db/db mice [39, 40]. Impaired MNCV was observed during the early phase.
of the diabetic syndrome. In morphological study, db/db mice showed loss or shrinkage of myelinated fibers in sural nerve and ventral root, and axonal atrophy [41,42]. In the retina, pathological changes such as loss of pericytes and acellular capillaries were observed [40].

3.2.2. Pharmacological Evaluation

There are many reports in which db/db mice showed anti-diabetic potency. Recently, it was reported that novel compounds, such as GPR119 agonists and PTP-1B inhibitors, show anti-diabetic effects in db/db mice [43,44]. A novel PTP-1B inhibitor that we developed also showed good glycemic control in db/db mice (Figure 4) [35]. Furthermore, combination therapy with pioglitazone, a PPARγ agonist, and alogliptin, a dipeptidyl peptidase (DPP)IV inhibitor, completely normalized β cell functions in db/db mice [45]. Recently, also, there have been many reports about pharmacological effects on diabetic complications in db/db mice. It was reported that treatment with various compounds, such as fibroblast growth factor (FGF) 21, erythropoietin, C-C chemokine receptor
type 2 (CCR2) inhibitor, and nuclear factor of activated T cells (NFAT) inhibitor, ameliorated diabetic nephropathy in db/db mice [46-49]. Interestingly, in erythropoietin or NFAT inhibitor treatment, one of the therapeutic targets is a protection effect against podocyte injury [47,48]. Tofogliflozin, a novel sodium/glucose cotransporter (SGLT)2 inhibitor, or celastrol, an NF-κB inhibitor, also improved renal injury in db/db mice [50,51].

3.3. KKAY Mouse

3.3.1. Background and Characteristics

Kondo et al. selected and established many mouse strains from Japanese native mice [52]. Among these inbred strains, Nakamura et al. found that the KK mouse is spontaneously diabetic [52,53]. Since diabetes and obesity in KK mice were relatively moderate, Nishimura et al. transferred the yellow obese gene (A') into KK mice by crossing yellow obese mice with KK mice [54]. The A' allele was associated phenotypically with yellow fur, hyperphagia, and obesity [55,56]. This congenic strain of KK mice has been named KK A' mouse.

In KK A' mice, diabetic characteristics, such as obesity, hyperinsulinemia, and hyperglycemia, were observed from young ages (6 - 8 weeks of age), but reverted apparently to normal after 40 weeks of age [57, 58]. Insulin resistance in KK A’ mouse is considered to be caused by various physiological changes, such as reduction in serum adiponectin levels, high activities of gluconeogenesis-enzymes in liver, and elevated production of TNF-α or other cytokines [59,60]. In pancreas of KK A' mice, pathohistological changes, such as degranulation, glycogen deposition, and hypertrophy β cells were observed at 5 - 10 weeks of age, suggesting that synthesis and release of insulin were increased with hyperinsulinemia [61]. In KK A' mice, renal lesions, such as diffuse glomerulosclerosis, nodular changes, and peripheral glomerular basement membrane (GBM) thickening were observed [53,57].

3.3.2. Pharmacological Evaluation

Anti-diabetic drugs that reduce insulin resistance or increase insulin sensitivity have been developed using KK A' mice. The first in the class of the TZD group of drugs, ciglitazone, was discovered in an in vivo screening system using KK A' mice [62]. Moreover, pioglitazone was selected by Ikeda et al. [63]. These compounds decreased hyperinsulinemia, hyperglycemia, and hyperlipidemia, accompanied by improvement of insulin resistance. TZDs are considered to exert insulin-sensitizing action by binding to PPARγ [64]. Treatment with vanadium complex showed an amelioration in diabetes, obesity, and hypertension in KK A' mice [65].

3.4. Tsumura Suzuki Obese Diabetics (TSOD) Mouse

3.4.1. Background and Characteristics

By the selective breeding of obese male mice of ddy strain and using indices of heavy body weight and appearance of urinary glucose, Suzuki et al. established two inbred strains in 1992: one with obesity and urinary glucose (TSOD) and the other without them (Tsumura Suzuki non obese: TSNO) [66,67].

The male TSOD mice showed diabetic symptoms, such as hyperphagia, polydipsia, obesity, hyperglycemia, hyperlipidemia, and hyperinsulinemia. Pancreatic islets of the TSOD mice showed hypertrophy with the increase in the number of β cells and complete or partial degranulation of β cells [66]. Iizuka et al. reported diabetic complications in TSOD mice in 2005 [68]. In the kidney, histological changes, such as thickening of the basement membrane in glomeruli and increase of the mesangial area were observed after 18 months of age. The motor neuropathy showed after 14 months of age, and the mice at 17 months of age showed weakness of front and hind
paws caused by neuron degeneration. Moreover, in sensory neuropathy, the threshold in tail pressure test decreased at 12 months of age. In histopathological analysis at sciatic nerves at 18 and 22 months of age, TSOD mice showed a decrease in the density of nerve fibers by endoneurial fibrosis and loss of these fibers. Furthermore, degenerative changes of myelinated fibers, separation of myelin sheaths with intralamellar edema and remyelination were observed. Kondo et al.

4. CONCLUSION

In this review, we overviewed the characteristic features of type 1 and type 2 diabetic mouse models and pharmacological evaluations using diabetic models. Various diabetic mouse models have been developed, and the models have played a key role in elucidating the pathogenesis of human diabetes and its complications. Moreover, diabetic mouse models are essential for developing novel drugs for diabetes and its complications. The importance of the mouse models will be a constant in the future, and establishment of novel mouse models is also necessary for further understanding of diabetic etiology and development of new therapies.

REFERENCES


Copyright © 2013 SciRes.


bis(allixunato)oxovanadium(IV) complex. *Biochemical and Biophysical Research Communications*, **345**, 945-950. http://dx.doi.org/10.1016/j.bbrc.2006.05.003

